Salt AI, a Los Angeles-based company specializing in contextual artificial intelligence for life sciences and health tech industries, has secured $10 million in funding to expand its AI platform capabilities. The investment round was led by Morpheus Ventures, with participation from Struck Capital, Marbruck Investments, and CoreWeave.
Addressing AI Complexity in Healthcare
The funding addresses a critical challenge facing biopharmaceutical and healthcare organizations: the complexity and opacity of traditional AI systems, often referred to as "black boxes." Salt AI's platform tackles this issue through a visual-first interface that maintains full coding capabilities, enabling teams to build, deploy, and manage AI-powered workflows across various business functions.
The platform supports multiple applications including drug discovery, clinical trials, revenue cycle management, and data navigation. This comprehensive approach allows organizations to integrate AI technologies across their operations while maintaining transparency and accessibility.
Proven Impact in Drug Discovery
Salt AI's effectiveness has been demonstrated at the Ellison Medical Institute, where the platform has accelerated research in computational biology since mid-2024. The institute has used Salt AI to design and analyze thousands of chemical compounds, resulting in the advancement of two promising protein candidates into more detailed laboratory studies.
The platform's flexible workflows enable researchers to continuously refine their digital design process, facilitating the transition from concept to experimentation. This capability represents a significant advancement in computational biology applications.
Technology Platform and Features
Central to Salt AI's offering is the Salt Matrix, a catalog of specialized data connectors, models, and tools tailored specifically for life sciences and healthcare teams. The platform enables rapid AI workflow construction through intuitive drag-and-drop features, simplifying collaboration between scientists, engineers, and business leaders.
The technology is built around three core strengths: enabling real-time collaboration across disciplines, delivering fast results through rapid deployment in private or on-premise environments, and maintaining strict compliance standards for enterprise-level adoption.
Strategic Growth Plans
The new funding will enable Salt AI to scale its global engineering teams and accelerate platform development. The company aims to grow its customer base among biopharmaceutical and healthcare organizations that are actively investing in advanced AI technologies.
"We are in the midst of a breakthrough moment in life sciences, with AI igniting unprecedented opportunities that were once out of reach," said Aber Whitcomb, CEO and Co-Founder of Salt AI. "No single AI model can unlock the future of medicine alone. The future belongs to ensembles, models working in synergy."
Brian Venturo, Co-founder and Chief Strategy Officer at CoreWeave, emphasized the platform's practical applications: "Salt AI is the kind of company CoreWeave aims to support, applying AI to one of society's most urgent challenges. Our AI cloud platform is purpose-built for complex models, enabling Salt AI to run workloads quickly and reliably."
The investment positions Salt AI to deepen its role in transforming how healthcare and biotech companies utilize AI, enabling faster innovation and more efficient operations across the industry.
